

GOVERNMENT OF PAKISTAN  
Ministry of National Health Services, Regulations and Coordination  
(Drug Regulatory Authority of Pakistan)

\*\*\*\*\*

Islamabad, the 14<sup>th</sup> February, 2022.

NOTIFICATION \*


S.R.O. 219 (I)/2022.- In exercise of the powers conferred by section 35 of the Drug Regulatory Authority of Pakistan Act, 2012 (XXI of 2012), the Federal Government, on the recommendations of the Policy Board of the Drug Regulatory Authority of Pakistan, is pleased to direct that the following amendments shall be made in Schedule-I to the said Act, namely:-

In the aforesaid Schedule, in paragraph 1, for sub-paragraph (7), the following shall be substituted, namely:-

“(7) No human vaccines, blood products (plasma derivatives medicinal products) and anti-sera (antivenoms and anti-rabies) shall be sold and used until a “Lot Release Certificate” from the Federal Government Analyst of the National Control Laboratory for Biologicals, Islamabad has been obtained.”

---

No. F. 3-71/2015-DDC(BD)

  
AAMAR LATIF,  
Deputy Director (Legal Affairs).

The Manager,  
Printing Corporation of Pakistan Press,  
Islamabad.